Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-26808 |
Trade Name | |
Synonyms | BGB26808|BGB 26808 |
Drug Descriptions |
BGB-26808 inhibits MAP4K1 (HPK1), which may decrease immunosuppression in the tumor microenvironment and increase cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
DrugClasses | MAP4K1 Inhibitor 8 |
CAS Registry Number | NA |
NCIT ID | C201143 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-26808 | BGB-26808 | 0 | 0 |
BGB-26808 + Tislelizumab | BGB-26808 Tislelizumab | 0 | 1 |